BioMarin (BMRN) PT Raised to $120 at Piper Jaffray
Tweet Send to a Friend
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE